IDWeek 2014: Vaccines

Early season influenza vaccination of patients with HIV may influence the risk of infection later in the season.

High-dose inactivated influenza vaccine (IIV-HD) demonstrates significantly improved immunogenicity compared to standard-dose inactivated influenza vaccine (IIV-SD) in older adults.

Substantial proportions of children who received the MenACWY-CRM conjugate vaccine between the ages of 2 and 10 years continued to have persistent antibodies against all four serogroups, with robust increases in antibody titers after a booster dose 5 years following the primary vaccination series

Concomitant administration of a licensed quadrivalent human papillomavirus (HPV4) vaccine and bivalent rLP2086, an investigational Neisseria meningitidis serogroup B (MnB) vaccine, generated robust immune responses to both vaccines in healthy adolescents.

The safety and immunogenicity of the investigational combination vaccine, DTaP5-IPV-Hib-HepB, when given as a 3-dose infant series, were comparable to equivalent licensed component vaccines.

Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in the prevention of vaccine-type community-acquired pneumonia (VT-CAP) or invasive pneumococcal disease (VT-IPD) declined with age.

Two investigational formulations of meningococcal MenABCWY vaccines have shown comparable immunogenicity to the licensed vaccines (MenACWY-CRM) and serogroup B (4CMenB), and the full outer membrane vesicle formulation gave higher GMT responses against B test strains.

Revaccination of children with live-attenuated influenza vaccine (LAIV) over 2 consecutive seasons did not reduce vaccine efficacy, and was similar to, or higher than, efficacy of a single LAIV administration in the second season.

The investigational Intradermal (ID) Quadrivalent Inactivated Influenza Vaccine (IIV4-ID) tested in a Phase 3 clinical trial during the 2012-13 influenza season produced antibody responses to B strains that were superior to a licensed split-virion trivalent influenza vaccine (IIV3-ID) containing the alternate strain, and noninferior for the A and matched B strains.

PCV13, a 13-valent pneumococcal conjugate vaccine, had an efficacy rate of 45.56% for preventing the first episode of vaccine-type pneumococcal community-acquired pneumonia (VT-CAP) in healthy adults 65 years of age and older.